Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > February 21, 2024
Daily News
February 21, 2024
- New Doctor Payment Disclosure Rule to Apply to Foreign Firms with Japan Subsidiaries
February 21, 2024
- Astellas CTO Eager to “Democratize” Digital Tools to Boost Productivity
February 21, 2024
- CureApp Kicks Off Japan PIII Study for NASH Therapeutic App
February 21, 2024
- Mitsubishi Tanabe Files OD Tablet Form for Canalia in Japan
February 21, 2024
- Japan to End Public Aid for COVID Drugs at March-End
February 21, 2024
- AMED Selects 6 VCs for Biotech Startup Funding Project
February 21, 2024
- MEXT to Ask University Hospitals to Create Reform Plan by June
February 21, 2024
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…